Page last updated: 2024-11-01

omeprazole and Deficiency, Factor 5

omeprazole has been researched along with Deficiency, Factor 5 in 1 studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Denier, C1
Bouteredjiret, T1
Dreyfus, M1
Lacroix, C1
Adams, D1

Other Studies

1 other study available for omeprazole and Deficiency, Factor 5

ArticleYear
Late and fatal deterioration of an intracerebral hemorrhage attributable to the onset of a high titer of acquired factor V inhibitor.
    European neurology, 2008, Volume: 60, Issue:4

    Topics: Aged; Anti-Ulcer Agents; Antihypertensive Agents; Cerebral Hemorrhage; Factor V; Factor V Deficiency

2008